We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA needs to provide for greater specificity in the cross-labeling of combination products and give its Office of Combination Products (OCP) a greater role in product reviews, according to a report issued last month by a panel of regulatory professionals.